FDA approves first biosimilar of 2018: 3 things to know

Pfizer earned FDA approval for its drug Retacrit — a biosimilar version of the anemia therapy Epogen/Procrit — May 15.

Here are three things to know.

1. Like Amgen's Epogen and Johnson & Johnson's Procrit, Retacrit may now be used to treat anemia linked to chronic kidney disease, chemotherapy or the use of zidovudine in HIV patients. The FDA also approved the biosimilar for use before or after surgeries to control blood loss.

2. The FDA previously rejected Retacrit in 2017, citing concerns over a manufacturing facility Pfizer would potentially use to produce the drug.

3. Retacrit is the first biosimilar approved in 2018 and the third biosimilar approved from Pfizer's portfolio.

More articles on supply chain:
Vermont first state to legalize drug importation from Canada
6 key proposals unveiled in Trump's plan to combat rising drug costs
62% of hospital leaders support Amazon as a medical supplier

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months